20.500.12556/RUL-148285 An unforeseen reality hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis Alemtuzumab is a humanized monoclonal antibody indicated for treatment of highly active relapsing-remitting multiple sclerosis (HA-RRMS). It binds to CD52 antigen and produces a rapid and prolonged lymphocyte depletion followed by a different pattern of T and B cell repopulation. Among others, its adverse events are autoimmune diseases. In this article, we present a patient with HA-RRMS, who was subsequently treated with alemtuzumab and afterwards developed hemophagocytic lymphohistiocytosis (HLH). Albeit rarely, HLH can be triggered by alemtuzumab treatment. HLH can favourably respond to prompt immunosuppressant therapy. Multidisciplinary approach by a team consisting of a neurology, hematology and rheumatology specialist is needed to treat this potentially lethal condition. multiple sclerosis alemtuzumab hemophagocytic lymphohistiocytosis side effects neuroimmunology drug therapy adverse effects multipla skleroza terapija z zdravili alemtuzumab škodljivi učinki hemofagocitna limfohistiocitoza true false true Angleški jezik Slovenski jezik Članek v reviji 2023-08-09 15:35:13 2023-08-09 15:35:18 2023-08-10 03:36:57 0000-00-00 00:00:00 2023 0 0 3 str. art. 107675 Vol. 228 2023 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.8 1872-6968 10.1016/j.clineuro.2023.107675 154225155 1-s2.0-S0303846723000914-main.pdf 1-s2.0-S0303846723000914-main.pdf 1 106CDFC42FA0C80E341F08EFB2F71F7F 8b73955b9feae8948017b9f65c8842122aa637e47c6574e8ad3897a38ae15b59 2805d499-36ba-11ee-aeaf-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=172376 https://www.sciencedirect.com/science/article/pii/S0303846723000914 0 8d3dfa10-36b9-11ee-aeaf-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=172375 Medicinska fakulteta 0 0 0